BR0014183A - Pharmaceutical compositions and methods of using secreted frizzled related protein - Google Patents

Pharmaceutical compositions and methods of using secreted frizzled related protein

Info

Publication number
BR0014183A
BR0014183A BR0014183-6A BR0014183A BR0014183A BR 0014183 A BR0014183 A BR 0014183A BR 0014183 A BR0014183 A BR 0014183A BR 0014183 A BR0014183 A BR 0014183A
Authority
BR
Brazil
Prior art keywords
methods
pharmaceutical compositions
secreted
related protein
sfrps
Prior art date
Application number
BR0014183-6A
Other languages
Portuguese (pt)
Inventor
Peter V N Bodine
Original Assignee
American Home Pruducts Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Pruducts Corp filed Critical American Home Pruducts Corp
Publication of BR0014183A publication Critical patent/BR0014183A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Animal Husbandry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Patente de Invenção: "COMPOSIçõES FARMACEUTICAS E MéTODOS DE USO DE PROTEìNA RELACIONADA FRIZZLED SECRETADA". São apresentadas composições farmacêuticas e métodos de uso na regulação de atividades de formação óssea em mamíferos, da SFRPs (proteínas relacionadas frizzied secretadas). As SFRPs são receptores secretados para Wnts, que são fatores de crescimento polipeptídicos importantes, que, como se conhece, regulam os processos biológicos fundamentais como polaridade tecidual, desenvolvimento embriónico e tumorigênese. Uma SFRP foi isolada em células de osteoblastos humanos e identificadas como SFRP-1 (também conhecida como SARP-2) e apresentada como sendo regulada por agentes osteogênicos nas células hOB de uma maneira seletiva de diferenciação modulando a vida de osteoblastos/pré-osteócitos.Invention Patent: "PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SECRETED FRIZZLED RELATED PROTEIN". Pharmaceutical compositions and methods of use in the regulation of bone formation activities in mammals, of SFRPs (related frizzied secreted proteins) are presented. SFRPs are secreted receptors for Wnts, which are important polypeptide growth factors, which, as is known, regulate fundamental biological processes such as tissue polarity, embryonic development and tumorigenesis. An SFRP was isolated in human osteoblast cells and identified as SFRP-1 (also known as SARP-2) and presented as being regulated by osteogenic agents in hOB cells in a selective way of differentiating by modulating the life of osteoblasts / pre-osteocytes.

BR0014183-6A 1999-09-13 2000-09-13 Pharmaceutical compositions and methods of using secreted frizzled related protein BR0014183A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39483299A 1999-09-13 1999-09-13
PCT/US2000/025035 WO2001019855A2 (en) 1999-09-13 2000-09-13 Pharmaceutical compositions and methods of using secreted frizzled related protein

Publications (1)

Publication Number Publication Date
BR0014183A true BR0014183A (en) 2002-05-14

Family

ID=23560597

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014183-6A BR0014183A (en) 1999-09-13 2000-09-13 Pharmaceutical compositions and methods of using secreted frizzled related protein

Country Status (11)

Country Link
EP (1) EP1212355A2 (en)
JP (1) JP2003512304A (en)
CN (2) CN102988957A (en)
AU (1) AU7131200A (en)
BR (1) BR0014183A (en)
CA (1) CA2383360A1 (en)
CZ (1) CZ2002903A3 (en)
IL (1) IL148421A0 (en)
MX (1) MXPA02002624A (en)
NZ (1) NZ529560A (en)
WO (1) WO2001019855A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02008487A (en) 2000-02-29 2002-12-13 Alcon Lab Inc Diagnostics and therapeutics for glaucoma.
US6600018B1 (en) 2000-04-10 2003-07-29 The United States Of America As Represented By The Department Of Health And Human Services Secreted frizzled related protein, sFRP, fragments and methods of use thereof
EP1318840A2 (en) * 2000-07-19 2003-06-18 Genzyme Corporation PHOSPHATONIN-RELATED GENE AND i METHODS OF USE THEREOF /i
JP4029041B2 (en) 2001-01-10 2008-01-09 アメリカ合衆国 sFRP and peptide motifs interacting with sFRP and methods of use thereof
EP1222933A1 (en) * 2001-01-15 2002-07-17 Academisch Ziekenhuis Leiden h.o.d.n., Leids Universitair Medisch Centrum Generation and/or reduction of new lung tissue in an affected lung, by modulation of the Wnt-pathway
WO2002081745A2 (en) * 2001-04-05 2002-10-17 Proskelia Pharmaceuticals Genes involved in osteogenesis, and methods of use
AU2002308557A1 (en) 2001-05-01 2002-11-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US7713526B2 (en) 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
GB0111004D0 (en) * 2001-05-04 2001-06-27 Univ Sheffield Screening method
CA2467258A1 (en) * 2001-11-15 2003-05-22 Kyowa Hakko Kogyo Co., Ltd. Agent for inducing embryonic stem cell to ectodermal cell, method for obtaining the same and use of the same.
ES2362681T3 (en) * 2002-12-05 2011-07-11 The Board Of Trustees Of The University Of Arkansas MOLECULAR DETERMINANTS OF MYELOMA OSTEOPATHY AND USE OF THE SAME.
WO2004090161A1 (en) * 2003-04-14 2004-10-21 Novartis Ag Gene expression associated with osteoblast differentiation
CN104726460A (en) * 2013-12-22 2015-06-24 上海交通大学医学院 Application of protein SFRP-5 in drug for treating psoriasis
CN107073117A (en) * 2014-08-26 2017-08-18 埃塔根有限公司 For recognizing the antibody of the specific motif of WLS albumen and pharmaceutical composition containing it
EP3696192A1 (en) * 2019-02-15 2020-08-19 Consejo Superior De Investigaciones Científicas Therapeutic target and monoclonal antibodies against it for the diagnosis and treatment of alzheimer´s disease
CN110361541A (en) * 2019-07-23 2019-10-22 上海交通大学医学院附属瑞金医院 SFRP2 and PCPE1 is preparing the application in fibrotic disease drug as joint target spot

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681701A (en) * 1993-07-12 1997-10-28 Mayo Foundation For Medical Education And Research Immortalized human fetal osteoblastic cells
CN1151744A (en) * 1994-07-04 1997-06-11 武田药品工业株式会社 Phosphonic acid compounds, their prodn. and use
WO1998016641A1 (en) * 1996-10-11 1998-04-23 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Isolation and method of using tissue growth-inducing frzb protein
AU7704498A (en) * 1997-05-29 1998-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Human frp and fragments thereof including methods for using them

Also Published As

Publication number Publication date
IL148421A0 (en) 2002-09-12
EP1212355A2 (en) 2002-06-12
CN1387537A (en) 2002-12-25
AU7131200A (en) 2001-04-17
JP2003512304A (en) 2003-04-02
CZ2002903A3 (en) 2002-07-17
MXPA02002624A (en) 2002-07-30
NZ529560A (en) 2005-05-27
CN102988957A (en) 2013-03-27
WO2001019855A3 (en) 2002-01-24
WO2001019855A2 (en) 2001-03-22
CA2383360A1 (en) 2001-03-22

Similar Documents

Publication Publication Date Title
BR0014183A (en) Pharmaceutical compositions and methods of using secreted frizzled related protein
CY1119263T1 (en) COMPOSITIONS AND METHODS FOR BONE BALANCING INCREASE
DE69839815D1 (en) USE OF PPAR-GAMMA ACTIVATORS FOR THE TREATMENT OF SKIN DISEASES
Avioli et al. Metabolic bone disease and clinically related disorders
EA200000298A1 (en) Prostaglandin agonists and their application for the treatment of bone diseases
Lee et al. Synergistic effect of growth factors on cell outgrowth from explants of rabbit anterior cruciate and medial collateral ligaments
DE69841850D1 (en) DIFFERENTIATION IN OSTEOBLASTS OF FAT-TISSUE-STROMAL CELLS AND ITS USES
BRPI0411552A (en) sclerostin-specific antibodies and methods to increase bone mineralization
ATE252134T1 (en) BIOACTIVE COMPOSITE MATERIAL FOR REPAIRING HARD AND SOFT TISSUE
ES2146552B1 (en) INHIBITING PEPTIDES OF TGF / 31
BR0214021A (en) Adipose-derived stromal cells, compositions and methods for the use of such cells in the treatment and repair of any defect associated with ocular tissue.
DE60224291D1 (en) SYSTEM FOR ANTIBODY EXPRESSION AND SYNTHESIS
BRPI0411112A (en) heterologous fusion protein, polynucleotide, vector, host cell, process for producing a heterologous fusion protein, method for treating a patient, and use of heterologous fusion protein
DK0409472T3 (en) Bone morphogenetic protein
AR014261A1 (en) BENZOTIAZEPINE HYPOLIPIDEMIC COMPOUNDS, COMPOSITIONS AND PROCESS FOR PREPARATION
BR0214029A (en) Methods and compositions for using stromal cells to support embryonic and adult stem cells
DE69724777D1 (en) PENTAFLUOROBENZEN SULPHONAMIDES AND ANALOGS
IT1260148B (en) USE OF HYALURONIC ACID PREPARATIONS FOR THE FORMATION OF BONE TISSUE
BRPI0411020A (en) gene expression profile, methods of identifying wnt pathway modular agents, preparing a gene expression profile, screening a remodeling agent associated with bone loading, and reagents that bind to proteins that modulate bone remodeling and / or bone mineralization, treating a bone mineralization disease or disorder, modulating bone mineralization in a cell and bone mineralization and / or bone remodeling in a patient, and determining whether a compound or composition enhances the loading effect. activity in bone cell activity / function and / or mineralization, candidate agent for treating a low bone mass condition and composition
DE69822668D1 (en) HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS APPLICABLE FOR CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION
ATE404668T1 (en) GROWTH FACTOR HOMOLOGUE ZVEGF-3
DE69726884D1 (en) HUMAN SDF-5 PROTEIN AND RELATED COMPOSITIONS
ES2382464T3 (en) Mutants of high activity growth factor
Calejo et al. Cellular complexity at the interface: challenges in enthesis tissue engineering
PT811001E (en) BENZOTIAZINE DIOXIDES AS ENDOTHELINE ANTAGONISTS

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2166 DE 10/07/2012.